[go: up one dir, main page]

CN111100128A - Synthetic method of Ribocini intermediate product and intermediate compound thereof - Google Patents

Synthetic method of Ribocini intermediate product and intermediate compound thereof Download PDF

Info

Publication number
CN111100128A
CN111100128A CN201811257137.XA CN201811257137A CN111100128A CN 111100128 A CN111100128 A CN 111100128A CN 201811257137 A CN201811257137 A CN 201811257137A CN 111100128 A CN111100128 A CN 111100128A
Authority
CN
China
Prior art keywords
compound
reaction
solvent
sodium
ribociclib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201811257137.XA
Other languages
Chinese (zh)
Other versions
CN111100128B (en
Inventor
张耀春
周福委
左小勇
周旭东
刘新军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guang'an Kingday Pharma & Chem Co ltd
Original Assignee
Guang'an Kingday Pharma & Chem Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guang'an Kingday Pharma & Chem Co ltd filed Critical Guang'an Kingday Pharma & Chem Co ltd
Priority to CN201811257137.XA priority Critical patent/CN111100128B/en
Publication of CN111100128A publication Critical patent/CN111100128A/en
Application granted granted Critical
Publication of CN111100128B publication Critical patent/CN111100128B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/584—Recycling of catalysts

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

The invention discloses a synthetic method of a Riboxini intermediate product, which comprises the following steps: the compound 2 is prepared by taking barbituric acid as a starting material through chlorination and hydroformylation; then condensation, ring closing, dechlorination, elimination and the like are carried out to obtain the Ribociclib intermediate 2-chloro-7-cyclopentyl-N, N-dimethyl-7H-pyrrolo [2,3-d]Pyrimidine-6-carboxamides. In addition, intermediate compounds are also disclosed. The synthesis method avoids the use of noble metal catalysis, has simple process route, easily obtained raw materials, mild conditions and effectively reduced production cost, and is suitable for large-scale production.

Description

Synthetic method of Ribocini intermediate product and intermediate compound thereof
Technical Field
The invention belongs to the field of pharmaceutical chemicals, and particularly relates to a synthetic method of a Ribocini intermediate product and an intermediate compound thereof.
Background
Ribociclib is a novel highly potent oral anticancer drug developed by Nowa. As a highly specific cell cycle dependent kinase (CDK4/6 dual inhibitor), the drug can remarkably inhibit the growth of a plurality of neurocytoma. Clinical research results show that the medicine has obvious curative effect when being used for treating the advanced breast cancer, thereby having wide market prospect.
The chemical name of Ribocini is: 7-cyclopentyl-N, N-dimethyl-2- [ [5- (1-piperazinyl) -2-pyridinyl ] amino ] -7H-pyrrolo [2,3-d ] pyrimidine-6-carboxamide, the structure of which is shown below.
Figure BDA0001842988720000011
Currently, the preparation of ribociclib is mainly performed by a key intermediate product, i.e., 2-chloro-7-cyclopentyl-N, N-dimethyl-7H-pyrrolo [2,3-d ] pyrimidine-6-carboxamide, and the preparation of the intermediate product is also widely reported.
PCT patent WO2010020675a1 discloses the synthesis of this key intermediate product, which is prepared as follows:
Figure BDA0001842988720000021
the route has the advantages of longer reaction steps, more complicated operation, low yield, and high process cost caused by using more noble metal catalysts.
The synthesis of this key intermediate product is also disclosed in US2012115878a1, which is an improvement over WO2010020675a1, and the preparation method is as follows:
Figure BDA0001842988720000022
compared with WO2010020675A1, the preparation method has a relatively short route and slightly improved coupling reaction yield, but uses highly toxic propargyl alcohol and still uses more noble metal catalysts; and finally, the oxidation and condensation reaction is completed in one step by adopting a one-pot method, although the reaction steps are shortened, a large amount of manganese dioxide is used, a large amount of solid waste is generated, and the operation risk is high due to the use of highly toxic sodium cyanide, so that the process amplification is not facilitated.
The Hangzhou KeChao Biotechnology Co., Ltd discloses a synthetic route of the key intermediate product in Chinese patent application CN 201610880076.7:
Figure BDA0001842988720000023
Figure BDA0001842988720000031
the route first prepares the propargylic acid derivative and then couples, thus shifting the most expensive one-step reaction to a relatively late position and increasing the yield. However, the following problems still exist with this route: the raw materials and reagents are expensive, the route is long, the catalyst still needs precious metal, and certain difficulty is brought to the amplification of the reaction. There is therefore still a need to find new synthesis methods which are simpler and more efficient.
Disclosure of Invention
The following is a summary of the subject matter described in detail herein. This summary is not intended to limit the scope of the claims.
The invention develops a preparation method of a Ribociclib intermediate product, namely 2-chloro-7-cyclopentyl-N, N-dimethyl-7H-pyrrolo [2,3-d ] pyrimidine-6-formamide, and the method has the advantages of simple process route, easily obtained raw materials, lower cost and higher yield, and is suitable for industrial production.
The invention aims to provide a synthetic method of a Ribociclib intermediate product.
It is another object of the present invention to provide intermediate compounds useful in the preparation of the above mentioned rebuscini intermediate products.
Specifically, in an embodiment of the present application, the present invention provides a method for synthesizing a ribociclib intermediate, wherein the ribociclib intermediate is 2-chloro-7-cyclopentyl-N, N-dimethyl-7H-pyrrolo [2,3-d ] pyrimidine-6-carboxamide, and the chemical structure of the ribociclib intermediate is shown as compound 9:
Figure BDA0001842988720000032
the method comprises the following steps:
1) in the presence of a Weilsmeier reagent and a chlorinated reagent, the barbituric acid, namely the compound 1, is subjected to hydroformylation and chlorination reaction to obtain a compound 2;
Figure BDA0001842988720000041
2) carrying out condensation reaction on the compound 2 and the compound 3 to obtain a compound 4;
Figure BDA0001842988720000042
3) carrying out a ring closing reaction on the compound 4 to obtain a compound 5;
Figure BDA0001842988720000043
4) in the presence of palladium-carbon and hydrogen, compound 5 is subjected to dechlorination reaction to generate compound 6;
Figure BDA0001842988720000044
5) the compound 6 undergoes elimination reaction to obtain a compound 7;
Figure BDA0001842988720000045
in the above synthesis method, wherein the substituent R in compound 4, compound 5, compound 6 and compound 7 is unsubstituted C1-C4 alkyl, phenyl substituted C1-C4 alkyl or alkyl substituted phenyl substituted C1-C4 alkyl, preferably, R is methyl, ethyl, tert-butyl or benzyl.
As an embodiment, the method for synthesizing the ribociclib intermediate product may further include: carrying out hydrolysis reaction on the compound 7 to obtain a compound 8;
Figure BDA0001842988720000051
then, reacting the compound 8 with dimethylamine to obtain the Ribociclib intermediate compound 9; or the compound 8 is subjected to acyl chlorination and then reacts with dimethylamine to obtain the Ribociclib intermediate compound 9;
Figure BDA0001842988720000052
as an embodiment, the above synthesis method may further include: and (3) directly reacting the compound 7 with dimethylamine to obtain the Ribociclib intermediate compound 9.
As an embodiment, the above synthesis method may further include: and (3) performing acyl chlorination on the compound 7 and then reacting with dimethylamine to obtain the Ribociclib intermediate compound 9.
Preferably, the weilsmeier reagent in step 1) is one or more selected from the group consisting of phosphorus oxychloride/N, N-dimethylformamide, oxalyl chloride/N, N-dimethylformamide, thionyl chloride/N, N-dimethylformamide, phosphorus oxychloride/N-methylformanilide.
Preferably, the chlorinating reagent in step 1) is selected from one or more of phosphorus oxychloride, oxalyl chloride and thionyl chloride.
Preferably, the reaction of step 1) is carried out in the presence of a solvent, or the reaction is carried out without a solvent (i.e., without additional solvent addition); here, the solvent of step 1) is selected from one or more of N, N-dimethylformamide, N-dimethylacetamide, and 1, 2-dichloroethane.
Preferably, the reaction temperature of the reaction in the step 1) is-10 ℃ to 150 ℃.
As an embodiment, the compound 3 in the step 2) may be prepared in the following manner: cyclopentanone and glycine ester (i.e., compound 10) are subjected to a reductive amination reaction to obtain a compound 3;
Figure BDA0001842988720000061
here, the definition of the substituent R in the compound 10 is the same as that in the above-mentioned compound 3;
preferably, the reducing agent in the reductive amination reaction can be selected from one or more of sodium triacetoxyborohydride, sodium cyanoborohydride, sodium borohydride and potassium borohydride; the reductive amination reaction can be carried out in the presence of a solvent, wherein the solvent used in the reductive amination reaction is selected from one or more of methanol, ethanol, water and tetrahydrofuran; the molar ratio of the cyclopentanone, the compound of formula 10 and the reducing agent is 1 (1-2) to (0.75-2.5), preferably 1 (1-1.5) to (1-1.5).
Preferably, the condensation reaction in step 2) may be performed in the presence of a base and a solvent; wherein the base is selected from one or more of sodium carbonate, potassium carbonate, cesium carbonate, sodium tert-butoxide, potassium tert-butoxide, lithium hexamethyl-silamine, sodium hexamethyl-silamine, diisopropylethylamine, triethylamine, 1, 8-diazabicyclo [5.4.0] undec-7-ene (DBU), triethylenediamine; the solvent in the step 2) is one or more selected from dichloromethane, 1, 2-dichloroethane, tetrahydrofuran, methanol, ethanol, chloroform, acetone, 1, 4-dioxane, N-dimethylformamide and N, N-dimethylacetamide. In step 2), a compound of formula 2: a compound of formula 3: the molar ratio of the alkali is 1: (0.9-1.5): (1-2), preferably 1: (0.95-1.2): (1.1-1.5).
Preferably, the condensation reaction in step 2) is carried out at a reaction temperature of-80 ℃ to 80 ℃, more preferably 0 ℃ to 60 ℃.
Preferably, the ring-closure reaction in step 3) may be carried out in the presence of a base and a solvent; wherein the base is selected from one or more of sodium methoxide, sodium ethoxide, sodium tert-butoxide, potassium tert-butoxide, sodium hydroxide, potassium hydroxide, diisopropylethylamine, triethylamine, 1, 8-diazabicyclo [5.4.0] undec-7-ene (DBU), triethylenediamine; the solvent in the step 3) is one or more selected from acetonitrile, toluene, dimethyl sulfoxide, tetrahydrofuran, 1, 4-dioxane, N-dimethylformamide and N, N-dimethylacetamide. In the step 3), the molar ratio of the compound of formula 4 to the base is 1 (1-3), preferably 1 (1.2-1.8).
Preferably, the reaction temperature of the ring-closure reaction in the step 3) is-30 ℃ to 50 ℃, more preferably 0 ℃ to 30 ℃.
Preferably, the dechlorination reaction in the step 4) may be performed in the presence of a base and a solvent; here, the solvent of step 4) is selected from one or more of methanol, ethanol, ethyl acetate, methyl acetate and butyl acetate; the base is selected from one or more of sodium carbonate, potassium carbonate, cesium carbonate, sodium tert-butoxide, potassium tert-butoxide, lithium hexamethyl-silamine, sodium hexamethyl-silamine, diisopropylethylamine, triethylamine, 1, 8-diazabicyclo [5.4.0] undec-7-ene (DBU), and triethylene diamine. In the step 4), the molar ratio of the compound of formula 5 to the base is 1 (0.8-2), preferably 1 (1-1.5).
Preferably, the pressure of the hydrogen gas in the step 4) is 0.1 to 3Mpa, and more preferably 0.1 to 0.5 Mpa.
Preferably, the reaction temperature of the dechlorination reaction in the step 4) is 0 ℃ to 80 ℃, and is further preferably 10 ℃ to 30 ℃.
Preferably, the elimination reaction in step 5) is carried out in the presence of an elimination reagent and a solvent, wherein the elimination reagent is selected from thionyl chloride/pyridine, trifluoroacetic anhydride/diisopropylethylamine, methanesulfonyl chloride/potassium carbonate, p-toluenesulfonyl chloride/potassium carbonate, and one of concentrated hydrochloric acid, hydrobromic acid, hydroiodic acid and sulfuric acid; the solvent of the step 5) is one or more selected from toluene, dichloromethane, chloroform, tetrahydrofuran and 1, 4-dioxane.
Preferably, the reaction temperature in the elimination reaction in the step 5) is-10 ℃ to 100 ℃, and more preferably 0 ℃ to 50 ℃.
Preferably, the compound 7 is hydrolyzed in the presence of alkali and solvent, and then is acidified to obtain a compound 8; the alkali used in the hydrolysis reaction is selected from one or more of sodium hydroxide, potassium hydroxide and lithium hydroxide; the solvent used in the hydrolysis reaction is one or more selected from tetrahydrofuran, methanol, ethanol, isopropanol, acetone, 1, 4-dioxane, N-dimethylformamide, N-dimethylacetamide, acetonitrile and water; preferably, the reaction temperature of the hydrolysis reaction is 0 ℃ to 80 ℃; the acid used for acidification is selected from one or more of hydrochloric acid, sulfuric acid and acetic acid.
Preferably, the reaction of compound 8 with dimethylamine is carried out in the presence of a condensing agent, a base and a solvent, wherein the condensing agent is selected from the group consisting of N, N '-dicyclohexylcarbodiimide, N, N' -diisopropylcarbodiimide, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride, 2- (7-azobenzotriazol) -N, N, N, N-tetramethylurea hexafluorophosphate, benzotriazol-N, N, N ', N' -tetramethylurea hexafluorophosphate, O- (6-chloro-1-benzotriazol-1-yl) -N, N, N ', N' -tetramethylurea hexafluorophosphate, (3H-1,2, 3-triazolo [4,5-b ] pyridin-3-yloxy) tris-1-pyrrolidinyl hexafluorophosphate One of a salt; the alkali is selected from one or more of sodium carbonate, potassium carbonate, cesium carbonate, diisopropylethylamine, triethylamine, 1, 8-diazabicyclo [5.4.0] undec-7-ene (DBU) and triethylene diamine; the solvent for the reaction is selected from one or more of dichloromethane, toluene, dimethyl sulfoxide, tetrahydrofuran, acetone, 1, 4-dioxane, N-dimethylformamide and N, N-dimethylacetamide. The reaction temperature of the reaction is 0 ℃ to 80 ℃.
Preferably, compound 8 is subjected to an acyl chlorination reaction in the presence of an acylating agent, and then is subjected to a condensation reaction with dimethylamine in a base and a solvent to produce the compound of formula 9. Here, the acylating agent is selected from one or more of thionyl chloride, oxalyl chloride, phosphorus oxychloride; the base is one or more of diisopropylethylamine, triethylamine, 1, 8-diazabicyclo [5.4.0] undec-7-ene and triethylene diamine; the solvent is one or more selected from dichloromethane, 1, 2-dichloroethane, tetrahydrofuran, chloroform, acetone, 1, 4-dioxane, N-dimethylformamide and N, N-dimethylacetamide. The reaction temperature of the acyl chlorination reaction is-10 ℃ to 90 ℃, preferably 0 ℃ to 80 ℃, and the reaction temperature of the condensation reaction is-10 ℃ to 60 ℃, preferably 5 ℃ to 35 ℃.
Preferably, the compound 7 is directly ammonolyzed with dimethylamine in a base and a solvent to generate the compound of the formula 9, wherein the base is selected from one or more of sodium carbonate, potassium carbonate, cesium carbonate, diisopropylethylamine, triethylamine, 1, 8-diazabicyclo [5.4.0] undec-7-ene (DBU) and triethylene diamine, and the solvent is selected from one or more of dichloromethane, 1, 2-dichloroethane, tetrahydrofuran, chloroform, acetone, 1, 4-dioxane, N-dimethylformamide and N, N-dimethylacetamide. The reaction temperature is 0 ℃ to 80 ℃, preferably 30 ℃ to 60 ℃. The molar ratio of the compound 7 to dimethylamine is 1 (1-3), preferably 1 (1.1-1.5).
In another aspect, the present invention provides an intermediate compound for synthesizing the above mentioned intermediate product, compound 9, which is selected from one of the following compounds:
Figure BDA0001842988720000091
here, the substituents R in the compounds 4,5 and 6 are each independently unsubstituted C1-C4 alkyl, phenyl-substituted C1-C4 alkyl or alkyl-substituted phenyl-substituted C1-C4 alkyl, preferably R is methyl, ethyl, tert-butyl or benzyl.
The invention provides a synthetic method of a Riboxini intermediate product, which comprises the following steps: the compound 1 is prepared by taking barbituric acid as a starting material through chlorination and hydroformylation; then carrying out condensation, ring closing, dechlorination, elimination and other reactions to obtain the Ribociclib intermediate 2-chloro-7-cyclopentyl-N, N-dimethyl-7H-pyrrolo [2,3-d ] pyrimidine-6-formamide. Compared with the prior art, the synthesis method not only avoids the use of noble metal catalysts, but also has the advantages of simple process route, easily obtained raw materials, mild conditions, effectively reduced production cost and suitability for mass production.
Detailed Description
Hereinafter, embodiments of the present invention will be described in detail in order to make the objects, technical solutions and advantages of the present invention more apparent. It should be noted that the embodiments and features of the embodiments in the present application may be arbitrarily combined with each other without conflict.
The main raw materials, reagents and solvents used in the experiment are all chemical pure products or analytically pure products sold in the market, and are directly used without purification.
The main instruments and models used in this experimental example: nuclear magnetic resonance apparatus: 600DD2 type, 600MHz, Agilent, USA; TMS is an internal standard; mass Spectrometry ESI-MS and HR-ESI-MS Finnigan LCQ Deca XP, electrospray ionization ion source.
Example 1
Figure BDA0001842988720000101
Adding phosphorus oxychloride (153.3g, 1000mmol) into a three-neck flask, stirring, cooling to-10-0 ℃ in an ice salt bath, slowly dropwise adding N, N-dimethylformamide (36.5g, 500mmol), controlling the temperature to be not higher than 5 ℃, stirring for 1 hour at a controlled temperature after dropwise adding is finished, adding barbituric acid 1(38.4g,300mmol), removing the ice salt bath, naturally returning to the room temperature, then, programming to 120 ℃, and stirring overnight. And (3) after TLC monitoring reaction is completed, slowly adding the reaction solution into ice water, separating out a large amount of solid, carrying out cold filtration, washing a filter cake until an effluent liquid is neutral to obtain a light yellow solid, and carrying out forced air drying at 50-60 ℃ to obtain a compound 2(58.3g, yield 92.5%). ESI M/z 211.01(M + 1).
Example 2
Figure BDA0001842988720000102
To a single-neck reaction flask were added methanol (200mL), cyclopentanone (16.8g,200mmol), glycine methyl ester (17.8g,200mmol), acetic acid (0.12g,2mmol) in that order. Stirring in an ice bath, adding sodium borohydride triacetate (63.6g,300mmol) in batches, heating to room temperature after the addition, stirring for 2 hours, monitoring the reaction completion by TLC, dropwise adding water (150g) to quench the reaction, concentrating under reduced pressure to remove methanol, adding 1mol/L hydrochloric acid (200mL), ethyl acetate (200mL), separating, detecting no product by an organic layer TLC, discarding, adjusting the pH of an aqueous phase to about 8 by adding solid sodium bicarbonate, extracting by ethyl acetate (200mL) for three times, combining organic phases, and concentrating under reduced pressure to dryness to obtain a brown oily substance, namely the compound 3-1(29.8g, yield 95.0%). ESI M/z 158.21(M + 1).
Example 3
Figure BDA0001842988720000103
Sequentially adding 2(31.6g,150mmol) and dichloromethane (300mL) into a three-neck flask, stirring in an ice bath, and cooling to 5-15 ℃; dropwise adding a dichloromethane (100mL) solution of a compound 3-1(25.9g,175mmol) and diisopropylethylamine (38g,200mmol), controlling the internal temperature to be 10-20 ℃, removing the ice bath after dropwise adding is finished, reacting at room temperature for 2-5 hours, adding 150mL of water after TLC monitoring reaction is finished, separating liquid, extracting a water phase with 100mL of dichloromethane, combining organic phases, washing with 200mL of saturated saline solution once, collecting the organic phases, concentrating to dryness to obtain brown semisolid, adding 50mL of ethyl acetate and 100mL of petroleum ether, heating to 50 ℃, stirring for 1 hour, cooling to 0-5 ℃, filtering, collecting filter cakes, and drying at 40-50 ℃ under reduced pressure to obtain a light yellow solid, namely a compound 4-1(44.3g, yield 89.2%). ESI M/z 332.12(M + 1).1H NMR(600MHz,CDCl3)δ10.44(s,1H),4.39(s,2H),4.26(s,3H),4.01–3.94(m,1H),2.17–2.06(m,2H),1.91–1.70(m,4H),1.65–1.49(m,2H)。
Example 4
Figure BDA0001842988720000111
Adding the compound 4-1(33.2g,100mmol) and acetonitrile (300mL) in a three-neck bottle in sequence, stirring in an ice bath, cooling to 0-10 ℃, and dropwise adding 1, 8-diazabicyclo [5.4.0]]Undec-7-ene (DBU) (18.2g,120mmol), controlling the internal temperature to be 5-20 ℃, removing the ice bath after finishing the dropwise addition, reacting for 0.5-2 hours at room temperature, monitoring the reaction process by TLC, concentrating under reduced pressure at 35-40 ℃ after the reaction is finished to obtain a brown solid, adding isopropanol (50g) and water (25g), stirring for 1 hour at normal temperature, filtering, leaching the filter cake with isopropanol (10mL) and water (5mL), and drying under reduced pressure at 40-50 ℃ to obtain a light yellow solid, namely the compound 5-1(29.6g, yield 89.2%). ESI M/z 332.06(M + 1).1H NMR(600MHz,CDCl3)δ5.44–5.38(m,1H),4.16(s,3H),3.83–3.77(m,1H),2.01–1.93(m,2H),1.83–1.66(m,4H),1.34–1.26(m,2H)。
Example 5
Figure BDA0001842988720000112
Adding the compound 5-1(26.6g,80mmol), ethyl acetate (200mL), 10% palladium carbon (2.66g) and potassium carbonate (13.6g,100mmol) into a single-mouth bottle, replacing with hydrogen, stirring at room temperature under hydrogen atmosphere, sampling every 0.5h to monitor the reaction process, after the reaction is completed, replacing hydrogen with nitrogen, filtering, rinsing filter cake ethyl acetate (20mL), collecting filtrate, and concentrating under reduced pressure to obtain an off-white solid, namely the compound 6-1(22.5g, yield 94.5%). ESI M/z 298.11(M + 1).1H NMR(600MHz,CDCl3)δ8.62(s,1H),5.28–5.19(m,1H),4.35(s,3H),3.66–3.59(m,1H),2.08–1.98(m,2H),1.95–1.77(m,4H),1.40–1.33(m,2H)。
Example 6
Figure BDA0001842988720000121
Sequentially adding a compound 6-1(20.8g,70mmol), dichloromethane (200mL), pyridine (11.1g,140mmol) into a three-neck flask, stirring in an ice salt bath, cooling to-5 ℃, slowly dropwise adding thionyl chloride (16.7g,140mmol), controlling the temperature to-5 ℃, stirring at room temperature for 2-4 hours after dropwise adding, monitoring the reaction by TLC, after the reaction is completed, slowly adding the reaction liquid into ice water (150g), separating, extracting once with aqueous phase dichloromethane (100mL), combining organic layers, concentrating until the mixture is dry to obtain a white-like solid, adding petroleum ether (100mL), pulping at room temperature for 1 hour, filtering, leaching once with the petroleum ether (20mL) of a filter cake, collecting the filter cake, and drying at 40-50 ℃ under reduced pressure to obtain a white solid compound 7-1(18.1g, wherein the yield is 92.7%). ESI M/z 280.10(M + 1).
Example 7
Figure BDA0001842988720000122
Adding the compound 7-1(16.7g,60mmol), methanol (50mL) and water (50mL) into a three-necked flask, uniformly stirring, adding a 10% sodium hydroxide solution (50g), and stirring at room temperature for 3-4 hours after the addition. After the reaction is finished, the methanol is removed through concentration under reduced pressure, dichloromethane (100mL) is added for back extraction once, the water phase is collected, the mixture is cooled to 5-20 ℃ through ice bath, 2.5mol/L hydrochloric acid (about 60mL) is added dropwise to adjust the pH value to 2-3, a large amount of white solid is separated out, the mixture is filtered, the filter cake is rinsed with water (100mL), the filter cake is collected, and air drying is carried out to obtain the white solid, namely the compound 8(14.9g, the yield is 93.5%). ESI M/z 266.15(M + 1).
Example 8
Figure BDA0001842988720000131
Adding the compound 8(13.2g and 50mmol) and N, N-dimethylformamide (65mL) into a three-necked bottle, uniformly stirring, carrying out ice bath, adding a mixture of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) (11.5g and 60mmol), controlling the temperature to be 0-10 ℃, dropwise adding triethylamine (12.1g and 120mmol) and a dimethylamine tetrahydrofuran solution (2.0M,37.5mL and 75mmol), reacting at room temperature for 6-10 hours after adding, adding water (200mL), ethyl acetate (200mL), separating, extracting with aqueous ethyl acetate (100mL) for 3 times, combining organic layers, washing with saturated saline (200mL) for 3 times, and concentrating the organic layer to be dry to obtain a light yellow solid. Adding methanol (20mL), heating, pulping, cooling, filtering, washing the filter cake with cold methanol (5mL), collecting the filter cake, and concentrating at 45-55 deg.C under reduced pressure to obtain off-white solid, i.e. compound 9(13.3g, yield 91.4%). ESI M/z 293.17(M + 1).
Example 9
Figure BDA0001842988720000132
Compound 8(2.64g,10mmol), chloroform (30mL), and thionyl chloride (1.78g,15mmol) were added to the reaction flask in this order, heated to 50 ℃ and stirred to react, and after TLC monitoring complete conversion of compound 8, chloroform and unreacted thionyl chloride were removed by distillation under pressure to give a pale yellow acid chloride intermediate. The acid chloride intermediate was dissolved in chloroform (30mL), stirred in an ice bath, triethylamine (1.21g, 12mmol) was added dropwise, followed by dimethylamine tetrahydrofuran solution (2.0M,7.5mL,15 mmol). After the addition was completed, the ice bath was removed, the mixture was stirred at room temperature for 1 to 2 hours, and after completion of the reaction, water (20mL) was added, the mixture was separated, and the aqueous phase was extracted once with chloroform (20mL), and the organic layers were combined and washed once with water (30 mL). The organic phase was collected and concentrated to dryness to give a pale yellow solid, which was slurried with 5mL of methanol, filtered, and dried to give off-white solid, Compound 9(1.89g, yield 64.7%).
Example 10
Figure BDA0001842988720000141
Adding a compound 7-1(2.79g,10mmol), 1, 4-dioxane (10mL) and a dimethylamine tetrahydrofuran solution (2.0M,7.5mL and 15mmol) in sequence into a reaction bottle, adding a reflux device, heating the reaction solution to 45-50 ℃, reacting for 8-12 hours, monitoring the reaction process, and supplementing the dimethylamine tetrahydrofuran solution (2.0M,2mL and 4mmol) if the reaction is not finished until the reaction is complete. After completion of the reaction, the reaction solution was dropped into ice water (50g), and a solid was precipitated and filtered. To obtain a pale yellow solid, slurried with methanol (5mL), filtered, and dried to obtain an off-white solid, i.e., Compound 9(1.33g, yield 45.5%).
Although the embodiments disclosed in the present application are described above, the descriptions are only for the convenience of understanding the present application, and are not intended to limit the present application. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the disclosure as defined by the appended claims.

Claims (10)

1. A synthetic method of a ribociclib intermediate product is disclosed, wherein the ribociclib intermediate product is 2-chloro-7-cyclopentyl-N, N-dimethyl-7H-pyrrolo [2,3-d ] pyrimidine-6-formamide, and the chemical structure of the ribociclib intermediate product is shown as a compound 9:
Figure FDA0001842988710000011
the method comprises the following steps:
1) in the presence of a Weilsmeier reagent and a chlorinated reagent, the barbituric acid, namely the compound 1, is subjected to hydroformylation and chlorination reaction to obtain a compound 2;
Figure FDA0001842988710000012
2) carrying out condensation reaction on the compound 2 and the compound 3 to obtain a compound 4;
Figure FDA0001842988710000013
3) carrying out a ring closing reaction on the compound 4 to obtain a compound 5;
Figure FDA0001842988710000014
4) in the presence of palladium-carbon and hydrogen, compound 5 is subjected to dechlorination reaction to obtain compound 6;
Figure FDA0001842988710000021
5) the compound 6 undergoes elimination reaction to obtain a compound 7;
Figure FDA0001842988710000022
in the above synthesis method, the substituent R in compound 3, compound 4, compound 5, compound 6 and compound 7 is each independently an unsubstituted C1-C4 alkyl group, a phenyl-substituted C1-C4 alkyl group, or an alkyl-substituted phenyl-substituted C1-C4 alkyl group, and preferably, R is a methyl group, an ethyl group, a tert-butyl group, or a benzyl group.
2. The method of claim 1, further comprising subjecting compound 7 to a hydrolysis reaction to provide compound 8;
Figure FDA0001842988710000023
then, reacting the compound 8 with dimethylamine to obtain the Ribociclib intermediate compound 9; or the compound 8 is subjected to acyl chlorination and then reacts with dimethylamine to obtain the Ribociclib intermediate compound 9;
Figure FDA0001842988710000024
3. the method of synthesis of claim 1, further comprising: and (3) directly reacting the compound 7 with dimethylamine to obtain the Ribociclib intermediate compound 9.
4. The method of synthesis of claim 1, further comprising: and (3) performing acyl chlorination on the compound 7 and then reacting with dimethylamine to obtain the Ribociclib intermediate compound 9.
5. The synthesis method according to any one of claims 1 to 4, wherein the Wilsmeier reagent in step 1) is selected from one or more of phosphorus oxychloride/N, N-dimethylformamide, oxalyl chloride/N, N-dimethylformamide, thionyl chloride/N, N-dimethylformamide, phosphorus oxychloride/N-methylformanilide; or
The chlorinating reagent in the step 1) is selected from one or more of phosphorus oxychloride, oxalyl chloride and thionyl chloride; or
The reaction in the step 1) is carried out in the presence of a solvent, wherein the solvent of the step 1) is one or more selected from N, N-dimethylformamide, N-dimethylacetamide and 1, 2-dichloroethane; alternatively, the reaction in step 1) is carried out in the absence of a solvent; or
The reaction temperature of the reaction in the step 1) is-10 ℃ to 150 ℃.
6. The synthesis method according to any one of claims 1 to 4, wherein the condensation reaction in step 2) is carried out in the presence of a base and a solvent; wherein the base is selected from one or more of sodium carbonate, potassium carbonate, cesium carbonate, sodium tert-butoxide, potassium tert-butoxide, lithium hexamethyl-silazane, sodium hexamethyl-silazane, diisopropylethylamine, triethylamine, 1, 8-diazabicyclo [5.4.0] undec-7-ene, triethylenediamine; the solvent in the step 2) is one or more selected from dichloromethane, 1, 2-dichloroethane, tetrahydrofuran, methanol, ethanol, chloroform, acetone, 1, 4-dioxane, N-dimethylformamide and N, N-dimethylacetamide; or
The reaction temperature of the condensation reaction in the step 2) is-80 ℃ to 80 ℃.
7. The synthesis method according to any one of claims 1 to 4, wherein the ring closure reaction in step 3) is carried out in the presence of a base and a solvent; wherein the base is selected from one or more of sodium methoxide, sodium ethoxide, sodium tert-butoxide, potassium tert-butoxide, sodium hydroxide, potassium hydroxide, diisopropylethylamine, triethylamine, 1, 8-diazabicyclo [5.4.0] undec-7-ene, triethylenediamine; the solvent in the step 3) is one or more selected from acetonitrile, toluene, dimethyl sulfoxide, tetrahydrofuran, 1, 4-dioxane, N-dimethylformamide and N, N-dimethylacetamide; or
The reaction temperature of the ring closure reaction in the step 3) is-30 ℃ to 50 ℃.
8. The synthesis process according to any one of claims 1 to 4, wherein the dechlorination reaction in step 4) is carried out in the presence of a base and a solvent; here, the solvent of step 4) is selected from one or more of methanol, ethanol, ethyl acetate, methyl acetate and butyl acetate; the base is selected from one or more of sodium carbonate, potassium carbonate, cesium carbonate, sodium tert-butoxide, potassium tert-butoxide, lithium hexamethyl-silamine, sodium hexamethyl-silamine, diisopropylethylamine, triethylamine, 1, 8-diazabicyclo [5.4.0] undec-7-ene, triethylenediamine; or
The pressure of the hydrogen in the step 4) is 0.1 to 3 Mpa; or
The reaction temperature of the dechlorination reaction in the step 4) is 0-80 ℃.
9. The synthesis method according to any one of claims 1 to 4, wherein the elimination reaction in step 5) is carried out in the presence of an elimination reagent selected from thionyl chloride/pyridine, trifluoroacetic anhydride/diisopropylethylamine, methanesulfonyl chloride/potassium carbonate, p-toluenesulfonyl chloride/potassium carbonate, and one of concentrated hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, and a solvent; the solvent in the step 5) is one or more selected from toluene, dichloromethane, chloroform, tetrahydrofuran and 1, 4-dioxane; or
The reaction temperature for the elimination reaction in the step 5) is-10 ℃ to 100 ℃.
10. An intermediate compound for the synthesis of compound 9, said intermediate compound being selected from one of the following compounds:
Figure FDA0001842988710000041
here, the substituent R in compound 4, compound 5 and compound 6 is each independently an unsubstituted C1-C4 alkyl group, a phenyl-substituted C1-C4 alkyl group, or an alkyl-substituted phenyl-substituted C1-C4 alkyl group, and preferably, R is a methyl group, an ethyl group, a tert-butyl group, or a benzyl group.
CN201811257137.XA 2018-10-26 2018-10-26 Synthetic method of Ribocini intermediate product and intermediate compound thereof Active CN111100128B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811257137.XA CN111100128B (en) 2018-10-26 2018-10-26 Synthetic method of Ribocini intermediate product and intermediate compound thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811257137.XA CN111100128B (en) 2018-10-26 2018-10-26 Synthetic method of Ribocini intermediate product and intermediate compound thereof

Publications (2)

Publication Number Publication Date
CN111100128A true CN111100128A (en) 2020-05-05
CN111100128B CN111100128B (en) 2022-09-06

Family

ID=70417789

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811257137.XA Active CN111100128B (en) 2018-10-26 2018-10-26 Synthetic method of Ribocini intermediate product and intermediate compound thereof

Country Status (1)

Country Link
CN (1) CN111100128B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111747960A (en) * 2020-06-12 2020-10-09 中山大学 A kind of substituted pyrazo[3,4-d]pyrimidine compound and its preparation method and application
CN113149915A (en) * 2021-03-01 2021-07-23 中国科学院成都有机化学有限公司 Method for synthesizing clonazepam compound
CN111100128B (en) * 2018-10-26 2022-09-06 广安凯特制药有限公司 Synthetic method of Ribocini intermediate product and intermediate compound thereof

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102918043A (en) * 2010-02-19 2013-02-06 诺瓦提斯公司 Pyrrolopyrimidine compounds as inhibitors of CDK4/6
CN103003280A (en) * 2010-02-19 2013-03-27 诺瓦提斯公司 Deuterated pyrrolopyrimidine compounds as inhibitors of CDK4/6
CN106478641A (en) * 2016-10-09 2017-03-08 杭州科巢生物科技有限公司 New synthetic method of Ribociclib intermediate
CN106928236A (en) * 2017-05-06 2017-07-07 青岛辰达生物科技有限公司 A kind of synthesis technique of Rui Boxini
CN106946880A (en) * 2017-05-06 2017-07-14 青岛辰达生物科技有限公司 A kind of method for preparing Rui Boxini intermediates
CN107118215A (en) * 2017-05-06 2017-09-01 青岛辰达生物科技有限公司 A kind of preparation method for treating breast cancer medicines Rui Boxini intermediates
WO2017162215A1 (en) * 2016-03-25 2017-09-28 正大天晴药业集团股份有限公司 Substituted pyrrolopyrimidine cdk inhibitor, pharmaceutical composition containing same and use thereof
CN107266451A (en) * 2016-04-07 2017-10-20 上海医药工业研究院 The preparation method of sharp cloth intermediate of auspicious cloth former times
WO2017211245A1 (en) * 2016-06-06 2017-12-14 深圳市塔吉瑞生物医药有限公司 Substituted pyrrolopyrimidine compound and application thereof
US9868739B2 (en) * 2010-11-10 2018-01-16 Novartis Ag Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
CN107922406A (en) * 2015-08-12 2018-04-17 伊莱利利公司 CGRP receptor antagonist
CN107936029A (en) * 2018-01-08 2018-04-20 南京奇可药业有限公司 A kind of method of synthesis Rui Boxini
WO2018140730A1 (en) * 2017-01-27 2018-08-02 Signalrx Pharmaceuticals, Inc. Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors
CN108586356A (en) * 2017-03-16 2018-09-28 杭州科巢生物科技有限公司 Rui Boxini new intermediates and its synthetic method for preparing Rui Boxini

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111100128B (en) * 2018-10-26 2022-09-06 广安凯特制药有限公司 Synthetic method of Ribocini intermediate product and intermediate compound thereof

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102918043A (en) * 2010-02-19 2013-02-06 诺瓦提斯公司 Pyrrolopyrimidine compounds as inhibitors of CDK4/6
CN103003280A (en) * 2010-02-19 2013-03-27 诺瓦提斯公司 Deuterated pyrrolopyrimidine compounds as inhibitors of CDK4/6
US9868739B2 (en) * 2010-11-10 2018-01-16 Novartis Ag Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
CN107922406A (en) * 2015-08-12 2018-04-17 伊莱利利公司 CGRP receptor antagonist
WO2017162215A1 (en) * 2016-03-25 2017-09-28 正大天晴药业集团股份有限公司 Substituted pyrrolopyrimidine cdk inhibitor, pharmaceutical composition containing same and use thereof
CN107266451A (en) * 2016-04-07 2017-10-20 上海医药工业研究院 The preparation method of sharp cloth intermediate of auspicious cloth former times
WO2017211245A1 (en) * 2016-06-06 2017-12-14 深圳市塔吉瑞生物医药有限公司 Substituted pyrrolopyrimidine compound and application thereof
CN106478641A (en) * 2016-10-09 2017-03-08 杭州科巢生物科技有限公司 New synthetic method of Ribociclib intermediate
WO2018140730A1 (en) * 2017-01-27 2018-08-02 Signalrx Pharmaceuticals, Inc. Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors
CN108586356A (en) * 2017-03-16 2018-09-28 杭州科巢生物科技有限公司 Rui Boxini new intermediates and its synthetic method for preparing Rui Boxini
CN107118215A (en) * 2017-05-06 2017-09-01 青岛辰达生物科技有限公司 A kind of preparation method for treating breast cancer medicines Rui Boxini intermediates
CN106946880A (en) * 2017-05-06 2017-07-14 青岛辰达生物科技有限公司 A kind of method for preparing Rui Boxini intermediates
CN106928236A (en) * 2017-05-06 2017-07-07 青岛辰达生物科技有限公司 A kind of synthesis technique of Rui Boxini
CN107936029A (en) * 2018-01-08 2018-04-20 南京奇可药业有限公司 A kind of method of synthesis Rui Boxini

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TINGFANG WANG， 等: "Design, synthesis and evaluation of pyrrolo[2,3-d]pyrimidine-phenylamide hybrids as potent Janus Kinase 2 inhibitors", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111100128B (en) * 2018-10-26 2022-09-06 广安凯特制药有限公司 Synthetic method of Ribocini intermediate product and intermediate compound thereof
CN111747960A (en) * 2020-06-12 2020-10-09 中山大学 A kind of substituted pyrazo[3,4-d]pyrimidine compound and its preparation method and application
CN111747960B (en) * 2020-06-12 2022-07-26 中山大学 A kind of substituted pyrazo[3,4-d]pyrimidine compound and its preparation method and application
CN113149915A (en) * 2021-03-01 2021-07-23 中国科学院成都有机化学有限公司 Method for synthesizing clonazepam compound
CN113149915B (en) * 2021-03-01 2024-03-15 中国科学院成都有机化学有限公司 Method for synthesizing clonazepam compound

Also Published As

Publication number Publication date
CN111100128B (en) 2022-09-06

Similar Documents

Publication Publication Date Title
ES2431618T3 (en) A process for the preparation of 6- (7 - ((1-aminocyclopropyl) methoxy) -6-methoxyquinolin-4-yloxy) -N-methyl-1-naphthamide and synthetic intermediates thereof
CN108383749B (en) The synthetic method of apalutamide and its intermediate
RU2509769C1 (en) Method of producing salts of tetrazole methanesulphonic acid and novel compound used therein
CN111100128B (en) Synthetic method of Ribocini intermediate product and intermediate compound thereof
CN101987843A (en) Method for synthesizing halofuginone hydrobromide and analogues thereof
CN112047888B (en) Method for synthesizing enzalutamide
RU2440978C2 (en) Method of producing 1-(3, 4-dichlorobenzyl)-5-octyl biguanide or salt thereof
EP2914574B1 (en) New process
EP2948441B1 (en) Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one
CN110759870B (en) Synthesis method of oxalagogri intermediate
CN113354573A (en) Method for large-scale production of alpha, alpha-terpyridine
RU2254334C2 (en) Method for preparing 6-methyl-2-(4-methylphenyl)-imidazolo[1,2-a]pyridine-3-(n,n-dimethylacetam ide), esters, crystalline esters, method for their preparing
CN110343117B (en) Process for the preparation of artemisinin derivatives
CN104177301A (en) Preparation method of dexrazoxane
CN115872906A (en) Levatinib impurity and preparation method thereof
CN114621155A (en) Method for preparing carbamatinib
CN103896889B (en) Lapatinib intermediate and its preparation method and application
CN105017219B (en) Synthetic method for p53-MDM2-binding inhibitor dyhydroxyl quinoline derivative
CN111100111B (en) Method for preparing benzothiophene derivative
CN104072403B (en) A kind of method preparing compound UNC1215
CN115572262B (en) Isoquinoline derivative and preparation method thereof
CN115417869B (en) Synthesis method of 6-bromoimidazole [1.2A ] pyridine-3-formamide
CN111116493A (en) A kind of method for preparing Apabetalone, intermediate and preparation method thereof
CN105111209B (en) Aza-indoline compound and method for preparing same
CN115197281B (en) Preparation method of etoposide intermediate

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant